AJDRAJNR - American Journal of Neuroradiology

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Remsen, L. G.
Right arrow Articles by Neuwelt, E. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Remsen, L. G.
Right arrow Articles by Neuwelt, E. A.

American Journal of Neuroradiology, Vol 17, Issue 3 411-418, Copyright © 1996 by American Society of Neuroradiology


ARTICLES

MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive diagnosis

LG Remsen, CI McCormick, S Roman-Goldstein, G Nilaver, R Weissleder, A Bogdanov, I Hellstrom, RA Kroll and EA Neuwelt
Department of Neurology, Oregon Health Sciences University, Portland 97201, USA.

PURPOSE: To determine if tumor-specific monoclonal antibodies conjugated to superparamagnetic monocrystalline iron oxide nanoparticles can be used to yield specific diagnoses with the use of MR imaging. METHODS: Monoclonal antibodies conjugated to monocrystalline iron oxide nanoparticles were given to nude rats with intracranial tumors either by intravenous injection, intraarterial injection with osmotic blood-brain barrier disruption, or direct intratumoral inoculation. Either L6, a tumor-specific antibody, or P- 1.17, a control isotype-matched antibody, was used. Coronal T1- weighted, T2-weighted, and spoiled gradient-recalled acquisition in the steady state images were obtained before, 30 minutes after, 6 hours after, and 24 hours after injection. RESULTS: Intravenous injection of greater than 2 mg of the tumor-specific antibody showed a specific pattern of enhancement of the tumors with the largest concentration of antibody in the area with the greatest density of tumor cells. The control antibody showed nonspecific changes. After intraarterial injection with barrier disruption to increase delivery globally or direct inoculation to increase delivery focally, no specific enhancement pattern was seen. CONCLUSION: Monoclonal antibodies conjugated with monocrystalline iron oxide particles may provide a method to obtain specific diagnoses with the use of MR imaging.


This article has been cited by other articles:


Home page
Genes Dev.Home page
T. F. Massoud and S. S. Gambhir
Molecular imaging in living subjects: seeing fundamental biological processes in a new light
Genes & Dev., March 1, 2003; 17(5): 545 - 580.
[Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
P. Varallyay, G. Nesbit, L. L. Muldoon, R. R. Nixon, J. Delashaw, J. I. Cohen, A. Petrillo, D. Rink, and E. A. Neuwelt
Comparison of Two Superparamagnetic Viral-Sized Iron Oxide Particles Ferumoxides and Ferumoxtran-10 with a Gadolinium Chelate in Imaging Intracranial Tumors
AJNR Am. J. Neuroradiol., April 1, 2002; 23(4): 510 - 519.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. W. M. Bulte, S.-C. Zhang, P. van Gelderen, V. Herynek, E. K. Jordan, I. D. Duncan, and J. A. Frank
Neurotransplantation of magnetically labeled oligodendrocyte progenitors: Magnetic resonance tracking of cell migration and myelination
PNAS, December 21, 1999; 96(26): 15256 - 15261.
[Abstract] [Full Text] [PDF]